Evommune (EVMN) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $48.00 price target on the stock.
Evommune (EVMN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $50.00 price target on the stock.
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine [Yahoo! Finance]
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Evommune (EVMN) was upgraded by Clear Str Llc to "strong-buy".